Company Information
USD
75.97
- (-2.2%)
NYSE:MRK, MERCK & CO., INC.
Industry: Drug Manufacturers - General
End of Day: 9 May 2025 GMT-4
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Address
126 East Lincoln Avenue
Website
Classification
Sector
Healthcare
Industry Group
Drug Manufacturers
Industry
Drug Manufacturers - General
Key Executives
Mr. Peter C. Wendell
Director
Mr. Douglas M. Baker, Jr
Director
Mr. Inge G. Thulin
Director
Mr. Richard R. DeLuca, Jr
Executive VP/President, Divisional
Ms. Patricia F. Russo
Director
Mr. Robert M. Davis
CEO/Chairman of the Board/Director/President
Mr. Thomas Henry Glocer
Director
Ms. Pamela J. Craig
Director
Dr. Risa J. Lavizzo-Mourey,M.D.
Director
Mr. Steven C. Mizell
Executive VP/Other Executive Officer
Ms. Kathy J. Warden
Director
Dr. Paul B. Rothman
Director
Mr. Sanat Chattopadhyay
Executive VP/President, Divisional
Ms. Mary Ellen Coe
Director
Mr. Chirfi Guindo
Other Executive Officer/Senior VP
Ms. Jennifer Zachary
Executive VP/General Counsel/Secretary
Ms. Caroline Litchfield
CFO/Executive VP
Dr. Christine E. Seidman
Director
Mr. David Michael Williams
Chief Information Officer/Executive VP/Other Executive Officer
Dr. Stephen L. Mayo, PhD
Director
Mr. Dean Y. Li
Executive VP/President, Divisional
Mr. Michael A Klobuchar
Chief Strategy Officer/Executive VP
Ms. Cristal N. Downing
Executive VP/Other Executive Officer
Mr. Jannie Oosthuizen
President, Geographical/Senior VP
Mr. Joseph Romanelli
President, Subsidiary/Senior VP
Mr. Dalton E. Smart, III
Chief Accounting Officer/Controller/Senior VP, Divisional
Mr. Dean Y. Li
President, Divisional
Ownership
Institution Holdings
Vanguard Group Inc
244,776,747 (9.665%)
Vanguard Group Inc. ( Junked)
244,767,034 (9.659%)
BlackRock Inc
201,836,434 (7.969%)
State Street Corporation
116,865,977 (4.614%)
Wellington Management Company LLP
85,595,999 (3.380%)
Vanguard Investments Australia Ltd
81,014,418 (3.199%)
Fidelity Management & Research Company LLC
74,881,669 (2.957%)
BlackRock Fund Advisors
70,588,641 (2.787%)
Geode Capital Management, LLC
55,428,245 (2.189%)
FMR Inc
42,800,017 (1.690%)
Individual Holdings
Mr. Robert M. Davis
348,327 (0.014%)
Mr. Richard R. DeLuca, Jr
135,783 (0.005%)
Ms. Caroline Litchfield
50,908 (0.002%)
Mr. Sanat Chattopadhyay
26,716 (0.001%)
Ms. Jennifer Zachary
29,058 (0.001%)
Mr. Steven C. Mizell
23,619 (0.001%)
Mr. Michael A Klobuchar
23,098 (0.001%)
Mr. Jannie Oosthuizen
23,327 (0.001%)
Mr. Chirfi Guindo
20,353 (0.001%)
Mr. David Michael Williams
19,812 (0.001%)
Funds Holdings
Vanguard US Total Market Shares ETF
79,666,791 (3.146%)
Vanguard Total Stock Market Index Fund
79,666,791 (3.146%)
Vanguard Institutional 500 Index Trust
62,622,250 (2.473%)
Fidelity 500 Index Fund
30,085,853 (1.188%)
SPDR® S&P 500 ETF Trust
29,745,270 (1.174%)
iShares Core S&P 500 ETF
26,363,303 (1.041%)
Vanguard Value Index Fund
21,090,730 (0.833%)
Schwab US Dividend Equity ETF™
19,487,148 (0.769%)
Health Care Select Sector SPDR® Fund
19,194,560 (0.758%)
Vanguard Institutional Index Fund
16,760,090 (0.662%)
Make Smart Investment Choices